First Patient Enrolled: 3TR Clinical Study Investigating Personalised Therapeutic Approaches in Multiple Sclerosis Has Started
Multiple sclerosis (MS) is one of seven chronic diseases being investigated within the 3TR project. The 3TR MS clinical trial aims to identify biomarkers that predict non-response to MS-specific disease-modifying therapies (DMTs) by collecting clinical data and biological samples from patients followed longitudinally at multiple time points over a 24 months period. A second aim is to evaluate the early pathophysiological changes affected by therapy and predict them for response or remission at 3 and 24 months. Indeed, despite the increasing number of DMTs available, some patients do not respond to treatment. This is because the complex elements in MS pathogenesis are still not fully understood. Therefore, markers and algorithms should be developed to predict the efficacy of the treatment before the onset of clinical symptoms in the context of an early and personalised treatment.
The data obtained from multiple innovative “omics” approaches will be integrated and combined with the data from the other clinical trials being simultaneously conducted as part of the 3TR project.
Enrolment in the 3TR MS studies started in June 2022 with the first patient from the IRCCS Policlinico Hospital (PI: Associate Professor Daniela Galimberti). The target is to include 350 patients from 11 European centres of excellence for the treatment of MS patients in the response/non-response biomarker study. The 3TR studies are proposed to understand the underlying mechanism of non-response to treatment with a view to provide a more effective and personalised therapy.
Similar clinical studies within the 3TR project focusing on patients with systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel diseases, asthma and chronic obstructive pulmonary disease will be conducted or are already underway.